EDIT vs TFX · rev $32.3M vs P/E 2083, rev $3.05B
Editas Medicine Inc (EDIT) versus Teleflex Incorporated (TFX) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Teleflex Incorporated (TFX) is a medical instruments & supplies company listed on NYSE.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported TFX revenue for 2024-12-31 was $3.05B. Net income was $69.7M. Revenue was up 2.4% from 2023-12-31 to 2024-12-31. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
EDIT currently screens at market cap $375.2M. TFX currently screens at market cap $5.53B and trailing P/E 2082.7.
Not investment advice. Open the EDIT and TFX stock pages for the full models.
Not investment advice.